The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 601–700 of 1,000
A Review of Antibody Therapeutics and Antibody-Related Technologies for Oncology
Scallon, B. J., Snyder, L. A., Anderson, G. M., Chen, Q., Li, Y., Weiner, L. M., & Nakada, M. T. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199196.97845.c3 · Cited by 38
Scallon, B. J., McCarthy, S. G., Radewonuk, J., Cai, A., Naso, M. F., Raju, T. S., & Capocasale, R. J. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.01.014 · Cited by 35
Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint
Giron, L. B., Papasavvas, E., Azzoni, L., Yin, X., Anzurez, A., Damra, M., Mounzer, K., Kostman, J. R., Sanne, I., Firnhaber, C. S., et al. (2020) · AIDS · doi:10.1097/qad.0000000000002476 · Cited by 34
“However, the role of galactosylation in ADCC activity is controversial [24].”
BackgroundTuning monoclonal antibody galactosylation using Raman spectroscopy‐controlled lactic acid feeding
Eyster, T. W., Talwar, S., Fernandez, J., Foster, S., Hayes, J., Allen, R., Reidinger, S., Wan, B., Ji, X., Aon, J. C., et al. (2020) · Biotechnology Progress · doi:10.1002/btpr.3085 · Cited by 45
“For example, increased galactosylation on IgG1 mAbs can impart antiinflammatory properties,(3) result in higher binding strength to FcγRIIIa whether afucosylated(4) or not,(5) and potentially increase antibodydependent cell-mediated cytotoxicity,(5) although earlier work has indicated galactosylation has no effect on…”
BackgroundBardor, M., Cabrera, G., Rudd, P. M., Dwek, R. A., Cremata, J. A., & Lerouge, P. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.08.009 · Cited by 33
“This suggests that the presence of a xylose residue on the core of plantibody N-glycans does not affect IgG performance and that the absence of the fucose residue may even increase its ADCC, as reported for nonfucosylated murine monoclonal antibodies [26].”
BackgroundArmour, K. L., Parry-Jones, D. R., Beharry, N., Ballinger, J. R., Mushens, R., Williams, R. K., Beatty, C., Stanworth, S. J., Lloyd-Evans, P., Scott, M. L., et al. (2005) · Blood · doi:10.1182/blood-2005-03-0989 · Cited by 34
“16 Different cell lines are known to produce antibodies with alternative glycosylation profiles which, in turn, affect potency in ADCC.(28,29) The different killing efficiencies may also be related to cell culture or purification conditions.”
BackgroundBiopharmaceutical Proteins: Opportunities and Challenges
Birch, J. R., & Onabanjo, E. O. (2005) · Humana Press eBooks · doi:10.1385/1-59259-922-2:001 · Cited by 48
Olivier, S., Jacoby, M., Brillon, C., Bouletreau, S., Mollet, T., Nerrière, O., Angel, A., Danet, S., Souttou, B., Guéhenneux, F., et al. (2010) · mAbs · doi:10.4161/mabs.12350 · Cited by 37
Fukushima, E., Yagi, Y., Yamamoto, S., Nakatani, Y., Kakehi, K., Hayakawa, T., & Suzuki, S. (2012) · Journal of Chromatography A · doi:10.1016/j.chroma.2012.02.052 · Cited by 34
Biosimilars: Practical Considerations for Pharmacists
Stevenson, J. G., Popovian, R., Jacobs, I. A., Hurst, S. I., & Shane, L. G. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017690743 · Cited by 37
Association of the IgG N -glycome with the course of kidney function in type 2 diabetes
Singh, S. S., Heijmans, R., der Meulen, C. C. M. V. C.-V., Lieverse, A. G., Gornik, O., Sijbrands, E. J. G., Lauc, G., & van Hoek, M. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-001026 · Cited by 40
Challenges for biosimilars: focus on rheumatoid arthritis
Akram, M. S., Pery, N., Butler, L., Shafiq, M. I., Batool, N., Rehman, M. F. U., Grahame-Dunn, L. G., & Yetisen, A. K. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1830746 · Cited by 40
Association of dementia with immunoglobulin G N-glycans in a Chinese Han Population
Zhang, X., Yuan, H., Lyu, J., Meng, X., Tian, Q., Li, Y., Zhang, J., Xu, X., Su, J., Hou, H., et al. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00055-w · Cited by 40
RNA interference technology to improve recombinant protein production in Chinese hamster ovary cells
Wu, S. (2009) · Biotechnology Advances · doi:10.1016/j.biotechadv.2009.03.002 · Cited by 48
Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity
Bakker, J. M., Bleeker, W. K., & Parren, P. W. H. I. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.06.865 · Cited by 34
Li, W. S., Ishihara, K., Yokota, T., Nakagawa, T., Koyama, N., Jin, J., Mizuno-Horikawa, Y., Wang, X., Miyoshi, E., Taniguchi, N., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwm107 · Cited by 33
Zhong, X., Cooley, C., Seth, N. P., Juo, Z. S., Presman, E., Resendes, N., Kumar, R. A., Allen, M., Mosyak, L., Stahl, M., et al. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24448 · Cited by 34
“Addition of bisecting GlcNAc, which also results in the removal of core fucose, significantly enhances ADCC activity (Davies et al., 2001; Shinkawa et al., 2003; Umana et al., 1999).”
Orthogonal Technologies for NISTmAb N-Glycan Structure Elucidation and Quantitation
Prien, J. M., Stöckmann, H., Albrecht, S., Millán‐Martín, S., Varatta, M., Furtado, M., Hosselet, S., Wang, M., Formolo, T., Rudd, P. M., et al. (2015) · ACS symposium series · doi:10.1021/bk-2015-1201.ch004 · Cited by 36
Liu, L., Jacobsen, F. W., Everds, N. E., Yao, Z., bin Yu, Y., Li, N., Clark, D., Nguyen, M. P., Fort, M. M., Narayanan, P. K., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.748707 · Cited by 33
“Isotype control mAbs, mAbs that had previously been shown to have effector functions and SEFL variants of these mAbs were evaluated in a variety of assays, including binding strength to human and cynomolgus Fc Rs in cell-based flow cytometry assays, binding to cynomolgus peripheral blood granulocytes, cynomolgus PBMC…”
BackgroundInfluentialChung, C., Wang, Q., Yang, S., Ponce, S. A., Kirsch, B. J., Zhang, H., & Betenbaugh, M. J. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26375 · Cited by 32
“example, it is well-known that the absence of a core fucose bound to the innermost N-acetyglucosamine increases mAbs’ affinity to the Fc gamma receptor III (FcγRIII), enhancing the overall antibody-dependent cellular cytotoxicity (ADCC) (Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundInfluentialImmunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models
Chea, L. S., & Amara, R. R. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1371594 · Cited by 35
“For example, IgG1 with low levels of fucose exhibit higher ADCC activity compared to fucose-rich antibodies [135,136].”
BackgroundKarampatzakis, A., Brož, P., Rey, C., Önfelt, B., Matos, G. D. S. C. D., Rycroft, D., Ambrose, A. R., & Davis, D. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641521 · Cited by 36
“ADCC assays have shown that lower Fc fucosylation leads to increased CD16-mediated killing (29, 30).”
BackgroundBeuger, V., Künkele, K., Koll, H., Gärtner, A., Bähner, M., BURTSCHER, H. J., & Klein, C. (2008) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20080220 · Cited by 33
Dorion-Thibaudeau, J., Raymond, C., Lattová, E., Perreault, H., Durocher, Y., & Crescenzo, G. D. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.04.010 · Cited by 42
Immune therapies for neuroblastoma
Navid, F., Armstrong, M., & Barfield, R. C. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.10.8358 · Cited by 36
Miranda, L. R., Duval, M., Doherty, H., Seaman, M. S., Posner, M. R., & Cavacini, L. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7132 · Cited by 35
Dall’Olio, F. (2018) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-2835-0_17 · Cited by 35
Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges
Teillaud, J. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.s15 · Cited by 37
“Humanised and chimeric IgG1 mAbs have been produced in a rat hybridoma cell line that expresses a lower level of α-1,6-fucosyltransferase, so that the secreted mAbs have lower fucosylated oligosaccharide than CHO-produced IgG1 [94].”
BackgroundModern Antibody Technology: The Impact on Drug Development
Moroney, S. E., & Plückthun, A. (2005) · Wiley eBooks · doi:10.1002/9783527620982.ch48 · Cited by 35
Gelderloos, A. T., Verheul, M. K., Middelhof, I., de Zeeuw‐Brouwer, M., van Binnendijk, R. S., Buisman, A., & van Kasteren, P. B. (2024) · Immunity & Ageing · doi:10.1186/s12979-024-00466-9 · Cited by 38
“It is furthermore possible that other antibody characteristics, for example differential glycosylation of the antibody Fc-tail or somatic hypermutation, have an important role in shaping the functional response upon repeated mRNA vaccination and these should be further investigated [8, 34–36].”
BackgroundProduction of Plant Made Pharmaceuticals: From Plant Host to Functional Protein
Nagels, B., Weterings, K., Callewaert, N., & Damme, E. J. M. V. (2012) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2011.616075 · Cited by 39
“effect and can be explained by the inhibition of fucose addition by the bisecting GlcNAc (Shinkawa et al., 2003; Jefferis, 2009).”
BackgroundOkbazghi, S. Z., More, A. S., White, D. R., Duan, S., Shah, I. S., Joshi, S. B., Middaugh, C. R., Volkin, D. B., & Tolbert, T. J. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.003 · Cited by 36
Liu, H., Nowak, C., Andrien, B. A., Shao, M., Ponniah, G., & Neill, A. (2017) · Biotechnology Progress · doi:10.1002/btpr.2498 · Cited by 35
“ever, this enhancement of ADCC is apparent only when a relatively high level of bisecting GlcNAC was present in antibodies with mainly core-fucosylated oligosaccharides.(62)”
BackgroundZhang, T., Sun, J., Li, J., Zhao, Y., Zhang, T., Yang, R., & Ma, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08363-w · Cited by 33
Zhang, H., Feng, L., Mello, P. D. A., Mao, C., Near, R. I., Csizmadia, E., Chan, L. L., Enjyoji, K., Gao, W., Zhao, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157431 · Cited by 35
Sweet and Sour: The Role of Glycosylation for the Anti-inflammatory Activity of Immunoglobulin G
Böhm, S., Kao, D., & Nimmerjahn, F. (2014) · Current topics in microbiology and immunology · doi:10.1007/978-3-319-07911-0_18 · Cited by 32
Klein, A. (2008) · PubMed · Cited by 33
Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis
Campbell, J., Lowe, D., & Sleeman, M. A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01183.x · Cited by 32
“This is typically achieved by engineering amino acids in the Fc domain (Lazar et al., 2006) or by modifying the carbohydrates at the glycosylation site Asn297 in the Fc domain (Shinkawa et al., 2003).”
BackgroundThe role of glycosylation in clinical allergy and immunology
Hale, R. C., Morais, D., Chou, J. S., & Stowell, S. R. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.09.003 · Cited by 31
Donor substrate binding and enzymatic mechanism of human core α1,6-fucosyltransferase (FUT8)
Kötzler, M. P., Blank, S., Bantleon, F. I., Spillner, E., & Meyer, B. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.08.018 · Cited by 31
Humanizing glycosylation pathways in eukaryotic expression systems
Khan, A. H., Bayat, H., Rajabibazl, M., Sabri, S., & Rahimpour, A. (2016) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-016-2172-7 · Cited by 37
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?
Menzella, F., Biava, M., Bagnasco, D., Galeone, C., Simonazzi, A., Ruggiero, P., & Facciolongo, N. C. (2019) · Drugs in Context · doi:10.7573/dic.212580 · Cited by 35
Wang, H., Li, X., Wang, X., Liu, D., Zhang, X., Cao, W., Zheng, Y., Guo, Z., Li, D., Xing, W., et al. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0099 · Cited by 35
“The addition of GlcNAc to the bisecting mannose of IgG N -glycans increases the binding affinity to Fc c RIIIA and ADCC (Shade and Anthony, 2013).”
Mimura, Y., Mimura‐Kimura, Y., Saldova, R., Rudd, P. M., & Jefferis, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818382 · Cited by 35
“In particular, nonfucosylation of IgG-Fc increases FcgRIIIa binding and ADCC ~50-fold (23, 24), which has been exploited for the development of therapeutic recombinant monoclonal antibodies for treatment of cancers, inflammatory and infectious diseases (25–28).”
BackgroundImmunoassay for quantification of antigen-specific IgG fucosylation
Šuštić, T., Coillie, J. V., Larsen, M. D., Derksen, N. I. L., Szittner, Z., Nouta, J., Wang, W., Damelang, T., Rebergen, I., Linty, F., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104109 · Cited by 32
Kaushal, R. S., Naik, N., Prajapati, M., Rane, S., Raulji, H., Afu, N. F., Upadhyay, T. K., & Saeed, M. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14227 · Cited by 33
“…Yan et al., 2008), peptide hormones (chorionic gonadotropin, luteinizing hormone, thyrotropin, and erythropoietin) (Park et al., 2005), antibodies (Shinkawa et al., 2003), lectins (Su et al., 2005), membrane- bound proteins (Tytgat & de Vos, 2016), collagen (Bann et al., 2000), and fibronectin…”
BackgroundRole of aberrant IgG glycosylation in the pathogenesis of inflammatory bowel disease
Miyoshi, E., Shinzaki, S., Fujii, H., Iijima, H., Kamada, Y., & Takehara, T. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500089 · Cited by 32
“For example, a deficiency of 1-6 GlcNAc (N-acetylglucosamine) branching on T-cell receptors leads to enhanced autoimmune activity [6], and the loss of core fucose on IgG molecules enhances antibody-dependent cytotoxicity [7].”
BackgroundAntibody expression in protease-deficient strains of the methylotrophic yeastOgataea minuta
Kuroda, K., Kitagawa, Y., Kobayashi, K., Tsumura, H., Komeda, T., Mori, E., Motoki, K., Kataoka, S., Chiba, Y., & Jigami, Y. (2007) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2007.00291.x · Cited by 30
Shinzaki, S., Iijima, H., Fujii, H., Kuroki, E., Tatsunaka, N., Inoue, T., Nakajima, S., Egawa, S., Kanto, T., Tsujii, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.008 · Cited by 30
Stamova, S., Koristka, S., Keil, J., Arndt, C., Feldmann, A., Michalk, I., Bartsch, H., Bippes, C. C., Schmitz, M., Cartellieri, M., et al. (2012) · Antibodies · doi:10.3390/antib1020172 · Cited by 34
“The efficiency of abs relying on triggering the innate immune mechanisms via their Fc region can be hindered by suboptimal interaction of Fc part of the mab with the Fc receptors of the immune effector cells, due to alternative glycosylation of the Fc fragment [72] or by the competition with the circulating IgGs [73].”
BackgroundPark, E. Y., Ishikiriyama, M., Nishina, T., Kato, T., Yagi, H., Kato, K., & Ueda, H. (2008) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2008.09.013 · Cited by 30
“Shinkawa et al. (2003) 14 reported that the most important carbohydrate structure in terms of the enhancement of 15 antibody-dependent cellular cytotoxicity (ADCC) is the fucose attached to the 16 innermost GlcNAc of the biantennary complex oligosaccharides.”
BackgroundGallagher, S., Yusuf, I., McCaughtry, T. M., Turman, S., Sun, H., Kolbeck, R., Herbst, R., & Wang, Y. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39503 · Cited by 34
Popp, O., Moser, S., Zielonka, J., Rüger, P., Hansen, S., & Plöttner, O. (2017) · mAbs · doi:10.1080/19420862.2017.1405203 · Cited by 32
“, prevents later addition of the core fucose by a-(1,6)-fucosyltransferase (FUT8) and blocks conversion of hybrid to complex type glycans.(17,25)”
BackgroundSchaffert, A., Hanić, M., Novokmet, M., Zaytseva, O. O., Krištić, J., Lux, A., Nitschke, L., Peipp, M., Pezer, M., Hennig, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03024 · Cited by 28
“Thus, IgG antibodies lacking fucose, sialic acid, and galactose have been described to have an enhanced pro-inflammatory activity, while antibody glycoforms rich in terminal sialic acid residues have an active anti-inflammatory and immunomodulatory activity (5, 14, 45, 46).”
BackgroundBlundell, P. A., Lu, D., Dell, A., Haslam, S., & Pleass, R. J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901145 · Cited by 29
“toxicity of IgG1 in the absence of fucose (4, 5); enhanced FcgRIIIA binding but rapid clearance from the circulation of IgG1 enriched for oligomannose structures (6–8); and im-”
BackgroundZhang, P., Chan, K. F., Haryadi, R., Bardor, M., & Song, Z. (2012) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2012_163 · Cited by 33
In vivo assay of human NK-dependent ADCC using NOD/SCID/γcnull (NOG) mice
Shiokawa, M., Takahashi, T., Murakami, A., Kita, S., Ito, M., Sugamura, K., & Ishii, N. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.145 · Cited by 29
Breaking the Glyco-Code of HIV Persistence and Immunopathogenesis
Colomb, F., Giron, L. B., Trbojević‐Akmačić, I., Lauc, G., & Abdel‐Mohsen, M. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00433-w · Cited by 29
Current targeted therapies in lymphomas
Chung, C. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz202 · Cited by 30
Functional exploration of the GH29 fucosidase family
Grootaert, H., Landuyt, L. V., Hulpiau, P., & Callewaert, N. (2020) · Glycobiology · doi:10.1093/glycob/cwaa023 · Cited by 32
“As a result, the corresponding antibodydependent cellular cytotoxicity (ADCC) effector function is elicited up to a hundredfold more efficiently (Shields et al. 2002; Shinkawa et al. 2003).”
BackgroundKjeldsen‐Kragh, J., & Bengtsson, J. (2020) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2020.09.004 · Cited by 29
Kaneko, M. K., Ohishi, T., Kawada, M., & Kato, Y. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100826 · Cited by 29
“We produced 60-mG2a-f, a non-fucosylated version of 60-mG2a to augment its ADCC activities because non-fucosylated antibodies are known to show higher ADCC activities [47,48].”
MethodInterchain Disulfide Bonding in Human IgG2 Antibodies Probed by Site-Directed Mutagenesis
Allen, M. J., Guo, A., Martinez, T., Han, M., Flynn, G. C., Wypych, J., Liu, D., Shen, W. D., Dillon, T. M., Vezina, C., et al. (2009) · Biochemistry · doi:10.1021/bi8022174 · Cited by 29
Yagi, Y., Yamamoto, S., Kakehi, K., Hayakawa, T., Ohyama, Y., & Suzuki, S. (2011) · Electrophoresis · doi:10.1002/elps.201100126 · Cited by 30
Therapeutic antibodies — Delivering the promise?
Hale, G. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.010 · Cited by 35
Recombinant antibodies for cancer therapy
Deonarain, M. P. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.8.1123 · Cited by 35
“Manipulating the expression of glycosyl-transferases can increase the level of bisecting N-acetyl glucosamine (N-Ac-Glc) sugar residue [114] or reduce the level of fucose [115] in the carbohydrate chain present on Asn-297 ( Figure 2 ).”
BackgroundGenetics of glycosylation in mammalian development and disease
Stanley, P. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00725-x · Cited by 54
Regulation of intracellular activity of N-glycan branching enzymes in mammals
Kizuka, Y. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107471 · Cited by 29
“Removal of core Fuc from therapeutic IgG was found to raise its antibody-dependent cellular cytotoxicity by (cid:1) 100-fold (101), so this approach is now used clinically.”
MethodGlycomics in Human Diseases and Its Emerging Role in Biomarker Discovery
Onigbinde, S. B., Adeniyi, M., Daramola, O. E., Chukwubueze, F. M., Bhuiyan, M. M. A. A., Nwaiwu, J. I., Bhattacharjee, T., & Mechref, Y. S. (2025) · Biomedicines · doi:10.3390/biomedicines13082034 · Cited by 44
Koenitzer, J. D., Müller, M. M., Leparc, G., Pauers, M., Bechmann, J., Schulz, P., Schaub, J., Enenkel, B., Hildebrandt, T., Hampel, M., et al. (2015) · Biotechnology Journal · doi:10.1002/biot.201400652 · Cited by 29
In vitroandIn vivoCharacterization of MDX-1401 for Therapy of Malignant Lymphoma
Cardarelli, P. M., Moldovan-Loomis, M.-C., Preston, B., Black, A., Passmore, D., Chen, T.-H. T., Chen, S., Liu, J., Kuhné, M. R., Srinivasan, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3222 · Cited by 30
Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy
Chung, C. G., & Poligone, B. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0293-y · Cited by 30
“Mogamulizumab is a defucosylated, humanized anti-CCR4 monoclonal antibody that, due to removal of fucose, elicits a more potent antibody-dependent cellular cytotoxicity (ADCC) than conventionally produced antibodies [40, 41].”
BackgroundWines, B. D., Billings, H., McLean, M. R., Kent, S. J., & Hogarth, P. M. (2017) · Current HIV Research · doi:10.2174/1570162x15666170320112247 · Cited by 31
“Analysis of the glycosylation of the Fc found that the absence of a bisecting fucose in the Asn297-linked carbohydrate greatly increased interaction of the Fc with FcγRIIIa [120-123].”
BackgroundSonneveld, M. E., Koeleman, C. A. M., Plomp, H. R., Wuhrer, M., van der Schoot, C. E., & Vidarsson, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00129 · Cited by 30
Recent Advances in the Chemical Biology of N-Glycans
Shirakawa, A., Manabe, Y., & Fukase, K. (2021) · Molecules · doi:10.3390/molecules26041040 · Cited by 30
Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective
Ajmeriya, S., Kumar, A., Karmakar, S., Rana, S., & Singh, H. (2022) · Journal of the Indian Institute of Science · doi:10.1007/s41745-021-00268-8 · Cited by 29
The Role of IgG Fc Region N-Glycosylation in the Pathomechanism of Rheumatoid Arthritis
Gyebrovszki, B., Ács, A., Szabo, D. A., Auer, F., Novozanszki, S., Rojkovich, B., Magyar, A., Hudecz, F., Vékey, K., Drahos, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105828 · Cited by 30
“Some studies indicate a role for bisection in the modulation of FcγRIIIa-mediated activities; however, data on this are not consistent [38,39].”
Li, G., Suzuki, H., Ohishi, T., Asano, T., Tanaka, T., Yanaka, M., Nakamura, T., Yoshikawa, T., Kawada, M., Kaneko, M. K., et al. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5221 · Cited by 30
“In particular, a core fucose deficiency on the Fc N ‑glycan has been revealed to enhance the Fc binding to the Fc γ RIIIa on the effector cells (23).”
Arimori, T., Mihara, E., Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M. K., Takagi, J., & Kato, Y. (2024) · Structure · doi:10.1016/j.str.2024.02.007 · Cited by 29
Strategy for the fine characterization of glycosyltransferase specificity using isotopomer assembly
Ito, H., Kameyama, A., Sato, T., Sukegawa, M., Ishida, H.-K., & Narimatsu, H. (2007) · Nature Methods · doi:10.1038/nmeth1050 · Cited by 28
Imamoto, Y., Tanaka, H., Takahashi, K. L., Konno, Y., & Suzawa, T. (2012) · Cytotechnology · doi:10.1007/s10616-012-9468-8 · Cited by 29
Donadio, S., Morelle, W., Pascual, A., Romi-Lebrun, R., Michalski, J.-C., & Ronin, C. (2005) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2005.091 · Cited by 28
Influence of Variable N-Glycosylation on the Cytolytic Potential of Chimeric CD19 Antibodies
Barbin, K., Stieglmaier, J., Saul, D., Stieglmaier, K., Stockmeyer, B., Pfeiffer, M. M., Lang, P., & Fey, G. H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000175684.28615.7b · Cited by 32
“Several reports have demonstrated that reduced fucosylation at the proximal GlcNAc resulted in enhanced ADCC in vitro.(5,27) A dramatically improved cytotoxic effect was observed for a completely defucosylated antibody produced in a CHO cell line, in which both alleles coding for the a1,6-fucosyltransferase had been d…”
BackgroundCosta, A. R., Withers, J., Rodrigues, M. E., McLoughlin, N., Henriques, M., Oliveira, R., Rudd, P. M., & Azeredo, J. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.12.002 · Cited by 32
“core fucosylation [24,32,33] and sialylation [34–37], have been shown to enhance the clinical efficacy of mAbs that exert their therapeutic effect by antibody-dependent cellular cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC) mediated”
BackgroundZong, H., Han, L., Ding, K., Wang, J., Sun, T., Zhang, X., Cagliero, C., Jiang, H., Xie, Y., Xu, J., et al. (2017) · Engineering in Life Sciences · doi:10.1002/elsc.201600255 · Cited by 28
“The disruption of FUT8 gene in CHO cells would eliminate the fucose from the IgG1 oligosaccharide [5,13].”
BackgroundInfluentialKondo, A., Li, W., Nakagawa, T., Nakano, M., Koyama, N., Wang, X., Gu, J., Miyoshi, E., & Taniguchi, N. (2006) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2006.10.011 · Cited by 28
The importance of IgG N-glycosylation in Health, Disease, and Neonatal hemochromatosis
Thaçi, K., & Anthony, R. M. (2025) · Glycoscience & Therapy · doi:10.1016/j.glycos.2025.100002 · Cited by 33
Kelly, R. M., Kowle, R. L., Lian, Z., Strifler, B. A., Witcher, D. R., Parekh, B. S., Wang, T., & Frye, C. C. (2017) · Biotechnology and Bioengineering · doi:10.1002/bit.26496 · Cited by 31
“…increase in binding affinity of afucosylated IgG1 for both high and low affinity human FcγRIIIa allotypes (Imai-Nishiya et al., 2007; Kanda, Imai-Nishiya, et al., 2007; Kanda, Yamada, et al., 2007; Masuda et al., 2007; Shields et al., 2002; Shinkawa et al., 2003; Yamane-Ohnuki et al., 2004).”
BackgroundGlyco-Mapper: A Chinese hamster ovary (CHO) genome-specific glycosylation prediction tool
Kremkow, B. G., & Lee, K. H. (2018) · Metabolic Engineering · doi:10.1016/j.ymben.2018.03.002 · Cited by 29
“Using a mAb (IgG1)-producing CHO cell line, Kanda et al. (2007) independently knocked out GMDS, Fut8 , and GMDS with an altered nutrient-feed containing fucose, thereby a ff ecting the anti-body-dependent cellular cytotoxicity through changes in fucosylation (Shinkawa et al., 2003).”
Liu, J., Mamatyusupu, D., Štambuk, J., Trbojević‐Akmačić, I., Zhang, J., Zhang, J., Wang, H., Meng, X., Razdorov, G., Menon, D. D., et al. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0052 · Cited by 31
“The presence of a bisecting GlcNAc is associated with enhanced ADCC activation via Fc c -RIIIa ligation (Zou et al., 2011) but to a lesser degree than the absence of core-fucose (Shinkawa et al., 2003).”
Marx, N., Dhiman, H., Schmieder, V., Freire, C. M., Ly, N. N., Klanert, G., & Borth, N. (2021) · Metabolic Engineering · doi:10.1016/j.ymben.2021.04.014 · Cited by 28
Cindrić, A., Krištić, J., Kavur, M. M., & Pezer, M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-70115-4_17 · Cited by 33
IgG1 conformational behavior: elucidation of the N-glycosylation role via molecular dynamics
Saporiti, S., Parravicini, C., Pergola, C., Guerrini, U., Rossi, M., Centola, F., & Eberini, I. (2021) · Biophysical Journal · doi:10.1016/j.bpj.2021.10.026 · Cited by 28
Comparative analysis of transferrin and IgG N-glycosylation in two human populations
Trbojević‐Akmačić, I., Vučković, F., Pribić, T., Vilaj, M. Ć., Černigoj, U., Vidič, J., Šimunović, J., Kępka, A., Kolčić, I., Klarić, L., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04685-6 · Cited by 33
Koles, K. (2004) · Glycobiology · doi:10.1093/glycob/cwh127 · Cited by 27
“This could be an advantage when considering expression of recombinant monoclonal antibodies in transgenic animals, because recently it has been shown that the absence of core fucose on human IgG strongly increases its antibody-dependent cellular cytotoxicity ( Shinkawa et al., 2003 ).”
BackgroundKim, Y. M., Park, J. S., Kim, S. K., Jung, K. M., Hwang, Y. S., Han, M., Lee, H. J., Seo, H. W., Suh, J., Han, B. K., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.021 · Cited by 30
6thAnnual European Antibody Congress 2010: November 29–December 1, 2010, Geneva, Switzerland
Beck, A., & Wurch, T. (2011) · mAbs · doi:10.4161/mabs.3.2.14788 · Cited by 28
“These novel structures should be watched carefully in the future.(1) Omid Vafa (Johnson & Johnson) summarized the most relevant preclinical and clinical data for the recently approved antibody golimumab (Simponi), approved in 2009 (US, Canada) for three major indications: rheumatoid arthritis, ankylosing spondylitis a…”
BackgroundSong, A., Myojo, K., Laudenslager, J., Harada, D., Miura, T., Suzuki, K. T., Kuni‐Kamochi, R., Soloff, R. S., Ohgami, K., & Kanda, Y. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.08.016 · Cited by 26
Self-citationIsoda, Y., Yagi, H., Satoh, T., Shibata‐Koyama, M., Masuda, K., Satoh, M., Kato, K., & Iida, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140120 · Cited by 32
Self-citationDevelopment of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies
Kaneko, M. K., Ohishi, T., Nakamura, T., Inoue, H., Takei, J., Sano, M., Asano, T., Sayama, Y., Hosono, H., Suzuki, H., et al. (2020) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2020.0019 · Cited by 26
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.